Phoenix Financial’s VYNE Therapeutics VYNE Stock Holding History

Phoenix Financial’s Portfolio VYNE Stock Details VYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-406	Closed	-$77K	–	365
2020 Q1	$77K	Buy	+406	New	+$127K	﹤0.01%	299

Other funds holding VYNE

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Phoenix Financial's VYNE Position: Q2 2020 in Review

Phoenix Financial sold out of VYNE Therapeutics (VYNE) in Q2 2020, closing a stake of 406 shares — an estimated $77K sold.

Phoenix Financial first reported a position in VYNE in Q1 2020 and held it in 1 quarter. The position peaked at $77K in Q1 2020. 106 funds tracked by Wall St. Rank hold VYNE as of Q2 2020.

Phoenix Financial reported no remaining VYNE Therapeutics position as of Q2 2020 after selling out during the quarter.
Phoenix Financial sold 406 VYNE Therapeutics shares in Q2 2020, an estimated $77K.
Phoenix Financial first reported a position in VYNE Therapeutics in Q1 2020 and held it in 1 quarter.
Phoenix Financial's VYNE Therapeutics position peaked at $77K in Q1 2020.
106 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q2 2020.

Based on Phoenix Financial's 13F filing for Q2 2020, filed 10 Aug 2020.